Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

British Journal of Cancer 2026 Open access

Read full text
Authors: Yvette Drew, Lucy Gilbert, Alejandro Martínez Bueno, Ana Oaknin, Víctor Moreno, Lydia Gaba Garcia, Gordon C. Jayson, Rebecca Kristeleit, Nehal J. Lakhani, Susana Banerjee, Daniela Matei, Amit Oza
+10 more Rowan Miller, Dennis Yiannakis, Maria-Pilar Barretina-Ginesta, Jerónimo Martínez García, Guanfang Wang, Jayalakshmi Miriyala, Amy Franke, Elisa Galvez, Lini Pandite, Debra L. Richardson
DOI: 10.1038/s41416-026-03430-0
Cited by: 2
References: 24

Fields of Study & Subjects

Phagocytosis and Immune Regulation Immunotherapy and Immune Responses Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Volume
134
Issue
12
Pages
1754–1763
Publication date
8 April 2026
Language
EN